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Abstract 
The urea cycle disorder (UCD) argininosuccinate lyase (ASL) deficiency, caused by a 
defective ASL enzyme, exhibits a wide range of phenotypes, from life-threatening neonatal 
hyperammonemia to asymptomatic patients, with only the biochemical marker 
argininosuccinic acid (ASA) elevated in body fluids. Remarkably, even without ever 
suffering from hyperammonemia, patients often develop severe cognitive impairment and 
seizures. The goal of this study was to understand the effect on the known toxic metabolite 
ASA and the assumed toxic metabolite guanidinosuccinic acid (GSA) on developing brain 
cells, and to evaluate the potential role of creatine (Cr) supplementation, as it was described 
protective for brain cells exposed to ammonia.  
We used an in vitro model, in which we exposed 3D organotypic rat brain cell cultures in 
aggregates to different combinations of the metabolites of interest at two time points 
(representing two different developmental stages). After harvest and cryopreservation of the 
cell cultures, the samples were analysed mainly by metabolite analysis, 
immunohistochemistry and western blotting. 
ASA and GSA were found toxic for astrocytes and neurons. This toxicity could be reverted in 
vitro by Cr. As well, an anti-apoptotic effect of ASA was revealed, which could contribute to 
the neurotoxicity in ASL deficiency. Further studies in human ASL deficiency will be 
required to understand the biochemical situation in the brain of affected patients, and to 
investigate the impact of high or low arginine doses on brain Cr availability. In addition, 
clinical trials to evaluate the beneficial effect of Cr supplementation in ASL deficiency would 
be valuable.  
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Take-home message 
Argininosuccinic acid and guanidinosuccinic acid, both metabolites present in ASL 
deficiency, are neurotoxic and affect mainly astrocytes but also neurons; creatine can revert 
this toxicity. These new findings should be investigated in human ASL deficiency to open up 
a possible novel therapeutic option in this disease. 
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Introduction 
Argininosuccinate lyase (ASL; MIM *608310) catalyzes as part of the urea cycle the 
breakdown of argininosuccinic acid (ASA) into fumarate and arginine. In the liver, this 
reaction is essential for ammonia detoxification and arginine synthesis (O'Brien and Barr 
1981). In addition, ASL is expressed in many nitric-oxide (NO) producing tissues like skin 
fibroblasts (O'Brien and Barr 1981), kidney (Ratner and Petrack 1953), small intestine (Wu et 
al. 1994), heart, brain (neurons and astroglia) (Braissant et al. 1999; Bizzoco et al. 2007), 
endothelial cells (Erez et al. 2011), muscle and erythrocytes (Tomlinson and Westall 1964). 
In these cells, ASL is part of the citrulline-NO cycle.  
A deficiency of ASL function (ASLD) leads to argininosuccinic aciduria (MIM #207900), 
the second most common urea cycle disorder (UCD) with an incidence of ~ 1:218,750 
(Summar et al. 2013). It is an autosomal recessive disorder caused by mutations in the ASL 
gene, which maps to 7q11.21 (O'Brien et al. 1986), spans 17,5 kb, has an open reading frame 
of 1,392 bp and harbors 16 coding exons. Most mutations reported so far (>160) are missense 
mutations distributed through exons 2 to 16 (of which exons 3, 4, 6, 7 and 9 harbor 41% of 
the mutations, while only accounting for 25% of the total ASL sequence) (Balmer et al. 2014). 
ASL functions as a homotetramer constituted by four 51 kDa monomers (Simard et al. 1986). 
Each monomer consists of three domains: domains 1 and 3 have a similar helix-turn-helix 
structure while domain 2 is formed by nine helices, three of which are involved in 
dimerization with another ASL monomer (Turner et al. 1997). Furthermore, there are three 
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highly conserved separated regions, which upon tetramerization come together and form an 
active site where each region contributes by a different monomer (Sampaleanu et al. 2001). 
ASLD can develop as either a severe neonatal onset form with life-threatening 
hyperammonemia or as a late onset with episodic hyperammonemia and long-term 
complications including liver dysfunction, neurocognitive deficits, arterial hypertension, 
behavioural abnormalities and learning disabilities. These long-term complications can occur 
even in absence of observed hyperammonemia crises. In fact, patients with ASLD have, in 
comparison to other UCDs, a remarkable poor outcome. This indicates that tissue-specific 
absence of ASL may cause these symptoms. In addition to the aforementioned clinical 
presentations, there are asymptomatic ASLD patients, possibly detected through newborn 
screening, that only show biochemical manifestations.  
The hallmark of the disease is the accumulation of ASA in plasma and urine (Baruteau et al. 
2017), a metabolite normally not detected (Häberle and Rubio 2014). The biochemical 
alterations in ASLD patients include increased plasma citrulline and decreased arginine 
(Häberle and Rubio 2014; Roze et al. 2007), which may affect all related metabolites: NO, 
polyamines, proline, glutamate, creatine (Cr) and agmatin. In fact, the loss of ASL led to a 
global NO deficiency in mice (Erez et al. 2011). Furthermore, it has been suggested that the 
decreased arginine levels cause a decoupling of NO synthase (NOS), which leads to 
accumulation of free radicals. These free radicals have the potential to attack accumulating 
ASA, hereby generating guanidinosuccinic acid (GSA) (Aoyagi et al. 1999), which could 
contribute to the neurotoxicity observed in ASLD patients. Although GSA has not yet been 
measured in brain, another guanidino compound, guanidinoacetate (GAA; Cr synthesis 
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pathway intermediate) was found elevated in the brain of ASLD patients (Baruteau et al. 
2017; van Spronsen et al. 2006), while in plasma and urine GAA was within normal ranges 
(Häberle and Rubio 2014). As well, a secondary Cr deficiency was suggested in these 
patients, at least in those not yet treated with arginine (Arias et al. 2004). It would be relevant 
to discern if such Cr deficiency is observed globally (plasma, urine, brain), or restricted to 
CNS as was the case for GAA (Baruteau et al. 2017; van Spronsen et al. 2006).   
In contrast to other UCDs and sometimes without ever suffering from hyperammonemia, 
ASLD patients often develop a severe neurologic disorder including mental retardation and 
seizures (Baruteau et al. 2017; Nagamani et al. 2012). Consequently, our aims were to 
understand the effects of those metabolites that likely accumulate in ASLD, ASA and GSA, 
on the developing brain cells. In addition, we wanted to test if Cr, proposed in trials to treat 
neurodegenerative disorders and found deficient in ASLD patients, had protective effects. To 
do so, we exploited an in vitro model, already used to study the effect of accumulating toxic 
metabolites in other metabolic diseases (Hanna-El-Daher et al. 2015; Jafari et al. 2013a), in 
which we exposed 3D organotypic rat brain cell cultures in aggregates to different 
combinations of the metabolites of interest at two time points (representing two different 
developmental stages). This model reproduced the production and accumulation of these 
metabolites during a metabolic crisis. After harvest and cryopreservation of the cell cultures, 
a thorough analysis of the samples was performed, including metabolite analysis, 
immunohistochemistry and western blotting. 
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Materials and Methods 
 
3D organotypic cultures of developing brain cells  
Handling of pregnant rats (Sprague–Dawley 300 g, Charles River) was done following all 
institutional and national guidelines for the care and use of laboratory animals (Swiss 
Academy for Medical Science rules). At E15.5 days the embryos were dissected to prepare 
3D primary cultures of brain cells in aggregates. For this purpose, the whole brains were 
mechanically dissociated and cultured under continuous gyratory agitation (80 rpm) in a 
serum-free and chemically defined medium, as previously described (Braissant et al. 2002). 
Spontaneously, all brain cells (including neurons, astrocytes and oligodendrocytes), 
reaggregate in an organized 3D network, resembling the tissue-specific pattern of the in vivo 
brain. These 3D cultures are thus considered as organotypic brain cell cultures, which can 
generate their own arginine and NO, thanks to the expression of NOS, argininosuccinate 
synthetase (ASS) and ASL (Braissant et al. 1999).  
To study the effect of metabolites accumulating in ASLD and to test the protective effect of 
specific molecules, cultures were treated by repeated administration of different combinations 
of compounds (see below), at two different time points representing different developmental 
stages: from day in vitro (DIV) 5 to DIV13, representing a neonatal brain, and from DIV14 to 
DIV22, representing an early infant brain (Figure 1A). Brain cell cultures were exposed to 
the following metabolites: argininosuccinate (ASA) at 1, 10, 100 or 1000 µM; GSA at 1, 10, 
30 or 100 µM; NH4Cl at 5 mM; Cr at 1 mM. Aggregates were harvested at DIV13 and 
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DIV22 by sedimentation, followed by three rinsing with cold PBS, and either frozen in liquid 
nitrogen for metabolite (liquid chromatography coupled to tandem–mass spectrometry, 
LC/MS–MS) and protein (western blotting) analysis, or embedded in cryo-medium (Tissue-
Tek O.C.T., Digitana) and frozen in liquid nitrogen-cooled isopentane for 
immunohistological analysis. Samples were kept at −80°C until use. Culture medium was 
harvested with every medium change (every 3 days until DIV14; every 2 days from DIV14 to 
22; Figure 1A) and kept at −80 °C for metabolite analysis by LC/MS–MS. 
 
Antibodies, western blotting and immunofluorescence 
For western blotting, primary antibodies against the following proteins were used: Actin 
(1:3000, A1978, Sigma), ASS (1:1000, ARP41366_T100, Aviva Systems), ASL (1:200, E-5 
sc-374353, Santa Cruz Biotechnology), cleaved caspase-3 (1:200, 9664) and caspase-3 
(1:1000, 9665) (Cell Signaling Technology), glial fibrillary acidic protein (GFAP, 1:1000, 
clone GA5, MAB 360, Millipore), medium weight neurofilament (NFM, 1:1000, clone NF-
09, sc51683, Santa Cruz technology), phosphorylated NFM (p-NFM, 1:500, clone NN18, 
MAB 5254, Millipore) and NOS1 (1:500, A-11 sc-5302, Santa Cruz Biotechnology). 
Secondary antibodies were horse radish peroxidase-conjugated goat anti-rabbit (1:3000, sc-
2301 Santa Cruz Biotechnology) and anti-mouse (1:3000, sc-516102 Santa Cruz 
Biotechnology). For immunofluorescence, primary antibodies against the following proteins 
were used: GFAP (1:100), myelin basic protein (MBP, 1:100) and cleaved caspase-3 (1:100). 
Secondary antibodies were goat anti-mouse, anti-rabbit or donkey anti-goat IgG labeled with 
Alexa Fluor® 555 (red) (Life Technologies). Western blotting was performed as described 
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(Hanna-El-Daher et al. 2015), loading 15 μg total protein in each gel lane. After 1st 
development, blots were stripped, re-probed and developed for the respective other genes. 
Images were taken with a Molecular Imager ChemiDoc XRS+ (BioRad) and quantified with 
the Image LabTM Software (BioRad). For immunofluorescence, 16 μm cryosections of 
aggregates were prepared and probed with the respective antibodies as described, including 
using Tyramide Signal Amplification (TSA, Molecular Probes) system for cleaved and total 
caspase 3 (Hanna-El-Daher et al, 2015). Sections were observed and digitized on an Olympus 
BX50 microscope equipped for red fluorescence; images were processed using the Cell Sens 
Imaging Software (Olympus). 
 
Measurement of metabolites and lactate dehydrogenase in the culture media 
Glucose, lactate and lactate dehydrogenase (LDH) were measured in culture media harvested 
at DIV13 and DIV22 using a COBAS 8000 analyzer (Roche, Switzerland). Ammonium in 
culture media was measured using an INTEGRA 200 analyzer (Roche, Switzerland). 
Intracellular concentrations of amino acids, as well as Cr and GAA, were measured in lysates 
of brain cell aggregates by LC/MS–MS as previously described (Hanna-El-Daher et al. 
2015).  
Nuclear magnetic resonance (NMR) spectroscopy measurements of intracellular metabolites 
were performed as previously described (Diserens et al. 2018). 
 
Statistical analysis 
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Data were expressed as mean ± standard error of the mean (SEM). Statistical significance of 
the differences between various conditions was determined by Student’s t-test (one way 
analysis of variance); p<0.05 was considered significant: + p<0.05 ; ++ p<0.01 ; +++ p<0.001. 
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Results 
 
Biochemical characterization of the ASA-exposed brain cell cultures 
 
Glucose and lactate in culture medium as indicators of metabolic activity 
In controls, glucose levels in immature cultures (DIV13) were higher than that of the later 
stage (DIV22) (Figure 1B). Upon addition of metabolites (ASA, GSA, NH4Cl, Cr), glucose 
did not change significantly in any condition in the immature culture. In contrast, at later 
stage, addition of 100 μM ASA caused a significant decrease in glucose levels; when ASA 
and NH4
+ were combined, glucose levels were even lower; and in presence of 100 μM GSA, 
glucose became undetectable (Figure 1B). In parallel, a significant increase in lactate was 
observed in controls at DIV22 with respect to that at DIV13 (Figure 1B). When immature 
cultures were stressed with NH4
+, lactate increased as well, as already described (Braissant et 
al. 2002). In contrast, lactate levels in the more mature stage remained essentially unchanged 
in every condition, except under 100 μM GSA which presented a 60% decrease in lactate, 
suggesting severe suffering of the cultures under this condition (see below). NMR 
spectroscopy measurements confirmed the increased glucose consumption at DIV22 with 
elevated intracellular glycolytic metabolites (glucose-1-phosphate and lactate) and the effect 
of 100 μM GSA on glucose and lactate. Addition of combined ASA, GSA with or without Cr 
did not lead to a significantly different metabolomic pattern defined by 39 intracellular 
metabolites detected by NMR (Supplementary Table 1). 
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Stage-dependent metabolization of ammonium 
While developing cultures (DIV13) showed NH4
+ levels of 100 µM (Figure 1C) in controls 
(as well as ASA-only and GSA-exposed conditions), mature cultures (DIV 22) showed mean 
NH4
+ levels of 40 µM (Figure 1C), illustrating the maturation of astrocytes expressing 
glutamine synthetase (the enzyme converting glutamate and NH4
+ to glutamine). These data 
are in accordance with our previous studies (Braissant et al. 2002). Accordingly, young 
cultures exposed to 5 mM NH4Cl showed extremely high levels of NH4
+ in culture medium 
(>2 mM), while mature cultures exposed to NH4
+ were able to metabolize it and showed 
levels of NH4
+ between 100 and 200 µM (Figure 1C). 
 
Lactate dehydrogenase (LDH) release as indicator of cell death 
While in all but one conditions tested LDH remained barely detectable in culture media, 100 
µM GSA exposure in mature cultures led to an important release of LDH, indicating 
suffering and massive cell death under this condition (Figure 1D). This was also reflected by 
the undetectable level of glucose at DIV22 of these GSA-exposed mature cultures, and by the 
severe reduction of gene expression for specific brain cell markers (e.g. GFAP for astrocytes; 
NFM/p-NFM for neurons; Figure 2). Interestingly, 100 µM GSA exposure in immature 
cultures did not provoke this severe condition.  
 
Differential toxicity of ASA and GSA exposure on brain cell types 
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While low levels of ASA exposure (e.g. 1 and 10 µM) did not appear to affect both 
developing (exposure DIV 5 to 13) and mature (exposure DIV 14 to 22) brain cells (see 
Figure 2), higher doses of ASA (e.g. 100 µM and 1 mM) showed differential neurotoxicity 
depending on the brain cell types. Similarly, a dose-dependent assay was first performed to 
evaluate the toxicity of GSA. While 1 and 10 µM GSA did not affect brain cells much (see 
Figure 2), 100 µM proved to be toxic and led to the rapid culture death (illustrated in Figure 
1D by massive LDH release in culture medium). We thus chose an intermediate dose of 30 
µM GSA in co-exposure with 100 µM ASA to evaluate the combined neurotoxicity of both 
ASA and GSA. 
Neurons were affected by ASA exposure, in particular in developing cultures (DIV 13) 
exposed to 100 µM ASA, as shown by decrease of both NFM and p-NFM (Figure 2A). 1 
mM Cr co-exposure prevented the ASA-induced NFM and p-NFM decrease. NFM and p-
NFM expression were not affected by ASA exposure in mature cultures (DIV22) (Figure 
2A). While co-exposure to 30 µM GSA (with ASA 100 µM; plus or minus 1 mM Cr) did not 
affect NFM and pNFM in mature cultures, 30 µM GSA interestingly appeared as protective 
as 1 mM Cr in developing cultures. As for astrocytes, 100 µM GSA strongly decreased p-
NFM expression in both stages of cultures. Co-exposure to 5 mM NH4Cl with 100 µM ASA 
strongly affected NFM and p-NFM expression in developing and mature cultures, this toxic 
effect being prevented by 1 mM Cr co-exposure in mature culture only (Figure 2A) 
Astrocytes appeared the most affected cell type, presenting decreased GFAP expression in 
both stages, as shown by immunohistochemistry and western blotting (Figure 2B). Co-
exposure to ammonium (5 mM) aggravated toxicity in both stages, showed by further 
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decrease in GFAP expression. Cr supplementation (1 mM) prevented ASA toxicity on GFAP 
(for both 100 µM and 1 mM ASA) with or without co-exposure to ammonium (Figure 2B). 
While 1 and 10 µM of GSA exposure did not appear to affect astrocytes, 100 µM GSA led to 
almost complete repression of GFAP expression in mature cultures. 30 µM GSA co-exposure 
did not appear to increase further the 100 µM ASA-induced astrocytic toxicity on GFAP. 
However, the presence of GSA impeached the protective effect of Cr supplementation, 
nevertheless demonstrating some GSA toxicity on astrocytes, both in developing and mature 
cultures (Figure 2B). 
In contrast, oligodendrocytes were not sensitive to ASA, at both 100 µM and 1 mM and in 
both stages, while ammonium co-exposure was detrimental to MBP expression in immature 
culture. Cr supplementation partially reverted ammonium toxicity on MBP expression in 
these immature cultures. No effect of 30 µM GSA and 100 µM ASA co-exposure was 
observed on oligodendrocytes (Figure 2C).  
 
Anti-apoptotic effect of ASA exposure, and ammonium-induced apoptosis 
100 µM ASA exposure appeared anti-apoptotic in developing cultures, as shown by both 
immunohistochemistry and western blotting for cleaved caspase 3, while total caspase 3 
remained stable. This effect was not observed in mature cultures. 30 µM GSA co-exposure 
with 100 µM ASA did not alter the ASA-induced anti-apoptotic effect, while 1 mM Cr co-
exposure, with or without GSA, further amplified the ASA-induced anti-apoptotic effect 
(Figure 3). Ammonium co-exposure with 100 µM ASA strongly stimulated apoptosis in 
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brain cells, in particular at the younger stage (DIV13). Interestingly, this effect was prevented 
by Cr (1 mM) co-exposure (Figure 3). 
 
Effects of ASA, GSA, ammonium and Cr on the citrulline-NO and Cr pathways 
With the aim of better understanding the mechanisms of ASA-induced toxicity to brain cells, 
and prevention by Cr supplementation, we decided to evaluate whether the expression of 
enzymes processing ASA (e.g. ASS and ASL; as well as NOS1, making together the 
citrulline-NO pathway) were affected by ASA exposure, with or without ammonium co-
exposure or Cr supplementation. These three proteins showed a strong decreased expression 
in younger cultures (DIV 13) at 100 µM ASA exposure (Figure 4A), while expression of 
ASS, ASL and NOS1 was barely affected in the mature cultures (Figure 4B). This effect on 
developing cells was prevented by 1 mM Cr supplementation. Intriguingly, 30 µM GSA co-
exposure with 100 µM ASA had the same protective effect as 1 mM Cr. Ammonium co-
exposure (with 100 µM ASA) further decreased ASS, ASL and NOS1 expression in younger 
cultures; Cr supplementation being protective only for NOS1 (Figure 4A). In mature cultures 
(DIV22), a detrimental effect of ammonium exposure was observed on NOS1 only (without 
any effect of ASA co-exposure), which was prevented also by Cr supplementation (Figure 
4B).  
We then evaluated whether the above-described effects on the citrulline-NO pathway could 
also affect the Cr synthesis pathway, as arginine, produced by the ASL reaction and entering 
AGAT reaction, is the limiting substrate for Cr synthesis. We thus measured, in the younger 
cultures (DIV13), the intracellular levels of arginine, GAA (the intermediate between AGAT 
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and GAMT reactions) and Cr by LC/MS-MS (Figure 4C). We show here that while 1 µM 
ASA appeared stimulatory on arginine, GAA and Cr levels, 100 µM ASA induced a 20% 
decrease of the three metabolites. Ammonium co-exposure induced a 25% decrease of both 
Arg and Cr at 1 and 10 µM ASA, while no further decrease was observed at 100 µM ASA. 
Ammonium co-exposure strongly decreased GAA levels. Cr supplementation strongly 
increased intracellular levels of Cr (+80%) but decreased GAA, and no change in Arg 
concentration could be observed. GSA did not affect intracellular levels of Arg, Cr and GAA, 
even at the highest concentration tested (100 µM). 
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Discussion 
Patients with ASLD often show worse neurological outcome than other UCDs (Erez 2013; 
Rüegger et al. 2014) and the reasons for this are not clear. We aimed here at a better 
understanding of this phenomenon by investigating the effect of the known toxic metabolite 
ASA and the assumed toxic metabolite GSA on brain cells, and by evaluating the role of Cr, 
as it was described protective for brain cells exposed to ammonia (Braissant 2010).  
We first investigated the overall biochemical situation of the 3D cell cultures in the presence 
of toxic metabolites. Apart of the normal increase of metabolic activity between immature 
and mature cultures (increase of glucose consumption and lactate release) and the already 
described metabolic stress induced by ammonium exposure (Braissant et al. 2002), no evident 
metabolic stress was observed through extracellular glucose, lactate, ammonium or LDH 
measures under ASA or GSA exposure, with the exception of high 100 µM GSA exposure 
which appeared extremely toxic to mature cultures (lactate strongly decreased; LDH release; 
protein expression extinction for GFAP and NFM for example). While GSA levels in human 
patients are not known, an increase of GSA seems likely given the known cerebral 
accumulation of another guanidino compound, guanidinoacetate, in ASLD (van Spronsen et 
al. 2006). GSA toxicity was further underlined by a decreased expression of astrocytic and 
neuronal markers in immunohistochemistry. The toxic effect of GSA was however not seen 
in all conditions. For instance, immature brain cells were more tolerant towards this 
metabolite and the reason for this remains unknown. We did not study in detail the 
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consequences of high NH4
+ since this was previously thoroughly characterized in the same 
system (Braissant 2010; Braissant et al. 2008; Braissant et al. 2002). 
We next wanted to know what cell types were mostly affected by ASA and GSA. This was 
evaluated in experiments with ASA alone or in co-exposure with GSA. Hereby, we found 
astrocytes being the most affected brain cell type, as shown by decreased GFAP expression in 
early and mature stages. This pattern was caused by ASA alone, and could be aggravated by 
addition of NH4
+. Interestingly, Cr could prevent this ASA toxicity, even when cells were 
exposed to high ASA doses (1 mM). The same was seen upon exposure to 30 µM GSA, 
while lower amounts GSA did not further increase ASA toxicity. 
In contrast, the effect of ASA alone or together with GSA was less severe but still clear in 
neurons at early stages. Again, Cr could prevent this ASA induced toxicity, and similarly 
when ASA was given together with NH4
+. The least affected cell type were oligodendrocytes, 
which only showed decreased MBP expression if ASA plus NH4
+ were given, suggesting an 
ammonium-only effect, supporting previous results (Cagnon and Braissant 2009). The pattern 
of affected brain cells possibly reflects levels of expression: ASL is expressed by neurons and 
astrocytes, while, in contrast, oligodendrocytes do not express ASL. Thus, due to the 
presence of ASL within neurons and astrocytes, ASA exposure might primarily affect these 
two cell types, for example through inhibition feedback loops on ASL expression, as well as 
on disturbance of the citrulline-NO cycle/NO production. 
Taken together, we prove here that ASA and GSA are both toxic to astrocytes, and to a lesser 
extent to neurons, with some dose dependent effect. While ASA is a proven metabolite in 
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ASLD, there is not yet enough evidence for increased GSA levels in brains of ASLD patients, 
although this can be assumed based on basic biochemistry. However, investigations in 
patients should be performed to measure GSA and hereby substantiate the role of GSA as an 
important factor in the pathophysiology of ASLD.  
The cause of the ASA and GSA toxicity remains partly unclear. We aimed at studying a 
possible impact of toxic metabolites on apoptosis. Surprisingly however, developing brain 
cells seemed to be protected by an anti-apoptotic effect of ASA (if given at 100 μM). Co-
exposure with GSA had the same effect, as the addition of Cr. Only when NH4
+ was added, 
this effect was reverted and, in contrast, brain cells went into apoptosis, confirming previous 
studies (Cagnon and Braissant 2008). It is still speculative but this may point towards an anti-
apoptotic effect of ASA, in which natural apoptosis occurring at these stages is hampered 
leading to surplus cells and neurological symptoms. The ASA neurotoxicity would then occur 
through inhibition of naturally and developmentally programmed cell death. An alternative 
(or additional) cause of ASA and GSA toxicity could be the decreased expression of the 
citrulline-NO pathway in developing cells. Again, Cr prevented this effect, as did a co-
exposure of 30 μM GSA and 100 μM ASA, while addition of NH4
+ enhanced the suppressive 
effect.  
Another explanation of the observed ASA toxicity and its prevention by Cr supplementation 
may be a change in the Cr synthesis pathway. ASA alone or in combination with NH4
+ 
caused relevant reduction of the entire Cr pathway. As described previously, NH4
+ co-
exposure strongly decreased GAA levels, most probably through AGAT inhibition (Braissant 
et al. 2008). While as expected Cr supplementation strongly increased intracellular levels of 
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Cr (+80%), no change in intracellular Arg concentration could be observed. Also, as 
expected, the increase of intracellular Cr by Cr supplementation led to a further decrease in 
GAA through negative feedback regulation on AGAT, as already shown in brain cells 
(Braissant et al. 2010). In contrast, the Cr pathway was not affected by GSA, even when 
given at a high concentration (100 µM).  
In summary, we identify ASA and GSA as toxic metabolites for mainly astrocytes and 
neurons. This toxicity can be reverted in vitro by Cr. Further, we reveal an anti-apoptotic 
effect of ASA, which may contribute to the neurotoxicity in ASLD. Our findings are relevant 
as they may have therapeutic implications. We propose studies in human ASLD to 
substantiate the biochemical situation (with a focus on ASA and guanidino compounds) in 
the CNS of affected patients, and to investigate the impact of high or low arginine doses on 
brain Cr availability. Lastly, we propose clinical studies aiming at investigating whether Cr 
supplementation can be beneficial in ASLD.  
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Figure legends 
 
Figure 1: Experimental setting and effects of ASA, GSA, ammonium and Cr exposure 
on extracellular basic metabolites and LDH. (A) Experimental setting showing the use of 
immature (DIV 5-13) and mature (DIV 14-22) 3D brain cell cultures in aggregates. Exposure 
to ASA (1,10,100,1000 µM), GSA (1,10,30,100 µM), NH4Cl (5 mM) and Cr (1 mM) were 
repeated at each medium change (DIV 5, 8, 11 for immature cultures; DIV 14, 16, 18, 20 for 
mature cultures); Harvests were done at DIV 13 and 22 respectively. (B-D) Effects of ASA, 
GSA, NH4Cl and Cr exposure on extracellular glucose and lactate (B), ammonium (C) and 
LDH (D). Mean±SEM; n: 4-5 depending on replicates; significance level as compared to 
controls: +p<0.05/++p<0.01/+++p<0.001 (Student’s T test). 
 
 
Figure 2: ASA exposure affects neurons and astrocytes, but not oligodendrocytes. 
(A) ASA-induced dysregulation of the neuronal (and axonal) markers NFM/p-NFM, and 
prevention by Cr. Western blot analysis of NFM and p-NFM in immature brain cell cultures 
(left side) shows that 100 µM ASA exposure induces a strong inhibition of both p-NFM 
(normally enriched in axons) and NFM. This effect is prevented by 1 mM Cr 
supplementation as well as, interestingly, by 30 µM GSA co-exposure, while 100 µM GSA 
exposure alone almost completely abolishes p-NFM expression. 5 mM NH4Cl co-exposure 
reinforces ASA-induced neurotoxicity on p-NFM and NFM, and prevents the protective 
effect of Cr, in contrast to NH4Cl exposure alone (Braissant et al. 2002). In contrast, in 
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mature cultures (right side), ASA did not show any toxicity for NFM and p-NFM, while 
GSA at both 10 and 100 µM induced a severe decrease of their expression. 5 mM NH4Cl co-
exposure with 100 µM ASA strongly inhibited both p-NFM and NFM expression, an effect 
prevented by Cr supplementation, in contrast to immature cultures. 
(B) ASA-induced dysregulation of the astrocytic marker GFAP, and prevention by Cr. (B) 
As shown by immunofluorescence, ASA exposure (100 µM and 1 mM) induces a decrease in 
GFAP expression in both immature and mature brain cell cultures, while 1 mM Cr co-
exposure appears to protect astrocytes against ASA toxicity. 5 mM NH4Cl co-exposure with 
100 µM ASA reinforces the ASA-induced toxicity, while Cr supplementation still appears to 
have a protective effect on GFAP. 30 µM GSA co-exposure with 100 µM ASA also 
reinforces the ASA-induced toxicity, while in that case Cr supplementation do not prevent the 
toxic effects on GFAP expression. By western blot analysis, we show the more pronounced 
toxicity of 100 µM ASA exposure on GFAP expression in immature cultures, as well as the 
cumulative toxicity of 5 mM NH4Cl and prevention by 1 mM Cr supplementation. Figure 2B 
also shows that 100 µM GSA exposure was deleterious to brain cell cultures, particularly for 
astrocytes on mature cultures in which GFAP expression was almost completely lost. 
(C) ASA and GSA exposures do not alter the expression of the oligodendrocytic marker 
MBP. We show by immunofluorescence that ASA exposure (100 µM and 1 mM), plus or 
minus 30 µM GSA or 1 mM Cr supplementation, does not alter the expression of MBP in 
oligodendrocytes. In contrast, 5 mM co-exposure with 100 µM ASA induced a decrease in 
MBP expression, which was more pronounced in immature cultures (DIV 13). This toxicity 
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of NH4
+, already observed in oligodendrocytes in this 3D culture system (Cagnon and 
Braissant 2009), could be partially prevented by Cr supplementation. 
For western blotting: Mean±SEM; n: 4-5 depending on replicates; significance level as 
compared to controls: +p<0.05/+++p<0.001 (Student’s T test). For immunofluorescence: Bar = 
100 μm. 
 
 
Figure 3: Anti-apoptotic effect of ASA and Cr exposure on brain cells. (A) Cleaved 
caspase 3 expression by immunofluorescence. ASA exposure (100 µM and 1 mM) decreases 
the level of cleaved caspase 3 in both immature and mature cultures, suggesting a decrease of 
natural apoptosis occurring in developing brain cells. 30 µM GSA co-exposure with 100 µM 
ASA appears to block this anti-apoptotic effect of ASA. 5 mM NH4Cl co-exposure with 100 
µM ASA strongly stimulates apoptosis, as already observed in the same system for 
ammonium exposure alone (Cagnon and Braissant 2008). This pro-apoptotic effect of 5 mM 
NH4Cl co-exposure is prevented by Cr supplementation. Bar: 100μm. (B) Western blot 
analysis of total and cleaved caspase 3. While 100 µM ASA exposure shows a non-
significant tendency to decrease apoptosis (decrease in cleaved caspase 3 expression) in 
immature cultures, this effect is strongly re-inforced by Cr supplementation, including under 
30 µM GSA co-exposure. This last effect was also observed in mature cultures. Mean±SEM; 
n: 4-5 depending on replicates; significance level as compared to controls: +++p<0.001 
(Student’s T test). 
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Figure 4: Effects of ASA on citrulline-NO and Cr pathways. (A,B) Western blot analysis 
of ASS, ASL and NOS1 expression in immature, respectively mature brain cell cultures. 
While no effect of ASA and Cr exposure was observed on ASS, ASL and NOS1 expression 
in mature cultures (B; DIV 22), 100 µM ASA exposure induced a decrease of ASS, ASL and 
NOS1 expression (A, DIV 13). This effect was prevented by 1 mM Cr supplementation as 
well as, interestingly, by 30 µM GSA co-exposure (as for p-NFM and NFM, see Figure 2). 5 
mM NH4Cl co-exposure with ASA prevented the protective effect of Cr, except partially for 
NOS1. This protective effect of Cr on ASA+NH4Cl toxicity for NOS1 expression was also 
observed in mature cultures (B). Mean±SEM; n: 4-5 depending on replicates; significance 
level as compared to controls: +p<0.05/+++p<0.001; significance level as compared to 
ASA+NH4Cl exposure: *p<0.05 (Student’s T test). (C) LC/MS-MS measure of intracellular 
arginine, Cr and GAA in immature cultures. While 1 µM ASA appeared stimulatory on the 
levels of Arg, Cr and GAA, suggesting a stimulation of the Cr synthesis pathway, higher 
ASA concentration induced a dose-dependent decrease of Arg, Cr and GAA. 5 mM NH4Cl 
co-exposure prevented the stimulatory effect of low dose ASA (1 µM) on Cr, most probably 
through inhibition of the AGAT enzyme as shown by strong decrease of GAA level. GSA 
exposure did not show any effect, at any concentrations tested, on Arg, Cr and GAA levels in 
immature cultures. Mean±SEM; n=3 per replicates in a representative experiment; 
significance level as compared to controls: +p<0.05/++p<0.01/+++p<0.001; significance level 
of Cr supplementation compared to the respective conditions of ASA+NH4Cl exposure 
without creatine: ***p<0.001 (Student’s T test). 
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